source
- FDA criticizes Lundbeck for webpages on migraine treatment VyeptiThe FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent la…Endpoints · 20d ago↗ source
- FDA quietly stops releasing CRLsThe FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information. The pause follows a law firm in AprilEndpoints · 20d ago↗ source
- The biggest health tech stories of 2026 — so farWe’re more than halfway through 2026, and it’s been an eventful year. Here are the five biggest developments we noticed in the first six months. Major AI companies are coming for healthcare.Endpoints